Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors with losses over $50,000 of the January 22, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against Osiris Therapeutics, Inc. (NASDAQ:OSIR).
If you suffered losses because of your purchase of Osiris securities between May 12, 2014 and November 20, 2015, contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/OSIR. The lawsuit was filed in the U.S. District Court for the District of Maryland and investors have until January 22, 2016 to move the court to act as lead plaintiff.
The complaint accuses the defendants of violations of the securities laws because Osiris failed to disclose during the Class Period that the Company overstated revenues from several contracts and failed to follow Generally Accepted Accounting Principles.
The news shocked investors when announced on November 16, 2015. Osiris disclosed that if they correctly recognized revenue for three contracts, it would result in substantial decreases in product revenues in 2014 and the first and second quarters of 2015. In addition, Osiris announced that these restatements would result in the Company missing its revenue targets in three of the last four quarters. Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
If you lost more than $50,000 in your investments in Osiris securities between May 12, 2014 and November 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Whistleblowers: Persons with non-public information regarding Osiris should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at (510) 725-3000 or email [email protected].
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter at http://www.hbsslaw.com/hagens-berman-investor-fraud-center/securitites-newsletter, and visit the blog at www.meaningfuldisclosure.com.


Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



